WO2024254461A3 - Methods and compositions for vaccine development and delivery - Google Patents

Methods and compositions for vaccine development and delivery Download PDF

Info

Publication number
WO2024254461A3
WO2024254461A3 PCT/US2024/033024 US2024033024W WO2024254461A3 WO 2024254461 A3 WO2024254461 A3 WO 2024254461A3 US 2024033024 W US2024033024 W US 2024033024W WO 2024254461 A3 WO2024254461 A3 WO 2024254461A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
delivery
vaccine development
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033024
Other languages
French (fr)
Other versions
WO2024254461A2 (en
Inventor
Hiep Vu
The Nhu NGUYEN
Sarah SILLMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NuTech Ventures Inc
Original Assignee
NuTech Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuTech Ventures Inc filed Critical NuTech Ventures Inc
Publication of WO2024254461A2 publication Critical patent/WO2024254461A2/en
Publication of WO2024254461A3 publication Critical patent/WO2024254461A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

This document describes methods and compositions that can be used to rapidly develop and deliver new vaccines.
PCT/US2024/033024 2023-06-07 2024-06-07 Methods and compositions for vaccine development and delivery Ceased WO2024254461A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363471614P 2023-06-07 2023-06-07
US63/471,614 2023-06-07

Publications (2)

Publication Number Publication Date
WO2024254461A2 WO2024254461A2 (en) 2024-12-12
WO2024254461A3 true WO2024254461A3 (en) 2025-01-09

Family

ID=93794636

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033024 Ceased WO2024254461A2 (en) 2023-06-07 2024-06-07 Methods and compositions for vaccine development and delivery

Country Status (1)

Country Link
WO (1) WO2024254461A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210196806A1 (en) * 2018-05-23 2021-07-01 Gritstone Oncology, Inc. Shared antigens
US20210252133A1 (en) * 2018-08-17 2021-08-19 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
US20220106257A1 (en) * 2020-07-16 2022-04-07 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
WO2022173730A1 (en) * 2021-02-09 2022-08-18 Virginia Commonwealth University Mini circular rna therapeutics and vaccines and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210196806A1 (en) * 2018-05-23 2021-07-01 Gritstone Oncology, Inc. Shared antigens
US20210252133A1 (en) * 2018-08-17 2021-08-19 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
US20220106257A1 (en) * 2020-07-16 2022-04-07 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
WO2022173730A1 (en) * 2021-02-09 2022-08-18 Virginia Commonwealth University Mini circular rna therapeutics and vaccines and methods of use thereof

Also Published As

Publication number Publication date
WO2024254461A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
BRPI1013780B8 (en) IMMUNOGENIC COMPOSITION USEFUL FOR IMMUNIZATION AGAINST STAPHYLOCOCCUS AUREUS, ITS PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION
EP4110383A4 (en) Compositions and methods for mucosal vaccination against sars-cov-2
EP3725328A3 (en) Novel adjuvant compositions
EP4494650A3 (en) Vaccine compositions having improved stability and immunogenicity
WO2013006842A3 (en) Self-replicating rna prime - protein boost vaccines
WO2015120110A3 (en) Novel pharmaceutical formulations
TW200806316A (en) Yeast-based vaccine for inducing an immune response
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
SA517390550B1 (en) Orodispersible Dosage Unit Containing an Estetrol Component
EP4461369A3 (en) Aerosolized compositions comprising mitochondria and methods of use thereof
EP4335851A3 (en) Pharmaceutical formulations and methods of use thereof
PH12019500330A1 (en) Porcine epidemic diarrhea preventative or therapeutic method, vaccine, and vaccine kit
EP4248992A3 (en) Foot-and-mouth disease vaccine
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AU2019366996A8 (en) Polymer-lipids and compositions
EP3000464A3 (en) Composition comprising farnesol and use thereof
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
WO2020012428A8 (en) New vaccines against avian reoviruses
ZA202104747B (en) Novel trypanosomal vaccine
MX2021011913A (en) Inactivated virus compositions and zika vaccine formulations.
WO2024254461A3 (en) Methods and compositions for vaccine development and delivery
AU2018347511A8 (en) Periodontitis vaccine and related compositions and method of use
ZA202104746B (en) Novel trypanosomal vaccine
EP4165075A4 (en) Hiv vaccine compositions, methods, and uses thereof
WO2005056769A3 (en) Orally-administered live bacterial vaccines for plague

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE